ACR: IL-12/23 Blocker Offers Long-Term Benefits in SLE

(MedPage Today) -- Responses were sustained out to 1 year with ustekinumab
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news
More News: Rheumatology | Stelara